Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

In Vivo Assessment of dbDNA GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> Lipoplex for GNE Myopathy: Improved Potency and Safety.

The journal of gene medicine·2026

Same author

Preclinical assessment of GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> lipoplex product development for GNE myopathy.

Future science OA·2026

Same author

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

JCO precision oncology·2026

Same author

A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC.

Cancer letters·2025

Same author

Clinical characterization and therapeutic targeting of fusion genes in oncology.

Future oncology (London, England)·2025

Same author

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product.

Scientific reports·2025

Same journal

The Safety of In-Hospital Delay and the Utility of dNLR in Elderly Patients With Acute Appendicitis.

World journal of surgery·2026

Same journal

Feasibility of Post-Operative Telehealth for Pediatric Surgical Patients in Malawi-A Mixed Methods Analysis.

World journal of surgery·2026

Same journal

Surgical Infrastructure and Workforce Readiness in Rwanda's District and Level 2 Teaching Hospitals: A Nationwide Facility-Based Survey.

World journal of surgery·2026

Same journal

From General Preparedness to Injury-Pattern-Specific Trauma Resource Planning.

World journal of surgery·2026

Same journal

Prevalence and Outcomes of Thrombocytopenia at ICU Admission Among Critically Ill Patients in a Resource-Limited Setting.

World journal of surgery·2026

Same journal

Transition of Care From Pediatric to Adult Services for Patients With Anorectal Malformations: A Qualitative Study.

World journal of surgery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Personalized cancer approach: using RNA interference technology.

John Nemunaitis¹, Donald D Rao, Shi-He Liu

¹Mary Crowley Cancer Research Centers, 1700 Pacific Avenue, Suite 1100, Dallas, TX, USA. jnemunaitis@marycrowley.org

World Journal of Surgery

|May 11, 2011

Summary

This summary is machine-generated.

Cancer

More Related Videos

DNA Vector-based RNA Interference to Study Gene Function in Cancer

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Related Experiment Videos

Last Updated: Jun 2, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

DNA Vector-based RNA Interference to Study Gene Function in Cancer

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Normal cell survival relies on complex gene signaling via DNA patterns.
Cancer cells exhibit altered survival dependent on a limited set of mutated DNA signals.
Targeting these specific cancer signals presents a therapeutic vulnerability.

Purpose of the Study:

To review RNA interference (RNAi) technology for targeting mutated DNA signals in cancer.
To outline a clinical pathway for developing RNAi-based personalized cancer therapy.
To highlight the potential of genomic-proteomic profiling in cancer management.

Main Methods:

Review of developing RNA interference (RNAi) technologies.
Analysis of genomic-proteomic profiling for molecular cancer characterization.
Description of a clinical development pathway for RNAi cancer therapies.

Main Results:

RNAi technology can specifically target and block signaling from mutated DNA.
Genomic-proteomic profiling enables molecular characterization of individual cancers.
Development of personalized therapies tailored to specific cancer signals is feasible.

Conclusions:

RNA interference offers a promising strategy to manage cancer by blocking critical mutated DNA signals.
Personalized therapy, guided by molecular profiling, represents a future direction in cancer treatment.
The integration of RNAi and personalized medicine holds significant clinical potential for cancer management.